Go Pro
David Nierengarten

David Nierengarten Analyst Performance

Managing Director, Equity Research at Wedbush

David Nierengarten is a stock analyst at Wedbush in the healthcare sector, covering 39 publicly traded companies. Over the past year, David Nierengarten has issued 118 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
169 Last 11 Years
Buy Recommendations
82.04% 137 Buy Ratings
Companies Covered
39 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy82.0%137 ratings
Hold18.0%30 ratings
Sell0.0%0 ratings

Out of 167 total stock ratings issued by David Nierengarten at Wedbush, the majority (82.0%) have been Buy recommendations, followed by 18.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
94.9% of companies on NASDAQ
37 companies
NYSE
2.6% of companies on NYSE
1 company
NYSEAMERICAN
2.6% of companies on NYSEAMERICAN
1 company

David Nierengarten, an analyst at Wedbush, currently covers 39 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
39 companies
100.0%

David Nierengarten of Wedbush specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
34 companies
87.2%
PHARMACEUTICALS
4 companies
10.3%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company
2.6%

About David Nierengarten

David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.

David Nierengarten's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Aktis Oncology stock logo
AKTS
Aktis Oncology
10/2/2026Reiterated Rating$18.38$35.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
9/29/2026Reiterated Rating$20.75$40.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
9/23/2026Reiterated Rating$11.95$22.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9/22/2026Lower Price Target$103.45$118.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/16/2026Reiterated Rating$5.80$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
9/16/2026Reiterated Rating$32.74$55.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
9/15/2026Reiterated Rating$47.39$64.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
9/15/2026Reiterated Rating$2.77$11.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
9/14/2026Reiterated Rating$55.41$64.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
9/14/2026Reiterated Rating$11.29$22.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
9/10/2026Reiterated Rating$76.51$100.00Outperform
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
9/9/2026Reiterated Rating$8.86$25.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
9/9/2026Boost Price Target$12.74$13.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
9/9/2026Reiterated Rating$90.79$123.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
9/9/2026Reiterated Rating$26.83$65.00Outperform
argenex SE stock logo
ARGX
argenex
9/3/2026Reiterated Rating$1,055.37$1,150.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
9/2/2026Downgrade$0.42$1.00Neutral
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
9/2/2026Boost Price Target$78.67$100.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
8/26/2026Lower Price Target$107.36$123.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
8/21/2026Reiterated Rating$56.41$64.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
8/20/2026Reiterated Rating$12.30$22.00Outperform
Aktis Oncology stock logo
AKTS
Aktis Oncology
8/19/2026Initiated Coverage$25.00$35.00Outperform
argenex SE stock logo
ARGX
argenex
8/18/2026Boost Price Target$987.84$1,150.00Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
8/13/2026Reiterated Rating$21.30$60.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
8/12/2026Boost Price Target$26.05$35.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
8/12/2026Boost Price Target$51.04$64.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
8/12/2026Boost Price Target$23.76$33.00Outperform
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
8/12/2026Boost Price Target$12.19$16.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
8/10/2026Reiterated Rating$51.45$58.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
8/6/2026Boost Price Target$19.10$30.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
8/5/2026Boost Price Target$103.85$130.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
7/30/2026Boost Price Target$28.99$40.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
7/30/2026Reiterated Rating$19.86$26.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
7/29/2026Boost Price Target$79.83$99.00Outperform
argenex SE stock logo
ARGX
argenex
7/28/2026Boost Price Target$888.82$1,050.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
7/24/2026Boost Price Target$19.99$20.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
7/23/2026Reiterated Rating$6.51$11.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
7/21/2026Reiterated Rating$22.22$31.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
7/21/2026Reiterated Rating$50.78$58.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
7/13/2026Reiterated Rating$38.03$55.00Outperform
They're not buying gold. They're buying this. (Ad)

Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.tc pixel

See the name, ticker, and full file now
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
7/10/2026Boost Price Target$15.44$17.00Neutral
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
7/6/2026Reiterated Rating$11.87$22.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6/30/2026Boost Price Target$96.15$110.00Neutral
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
6/29/2026Boost Price Target$59.96$72.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6/23/2026Reiterated Rating$0.87$5.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
6/22/2026Downgrade$132.61$135.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
6/16/2026Reiterated Rating$81.95$100.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
6/15/2026Reiterated Rating$13.39$12.00Neutral
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
6/12/2026Reiterated Rating$21.51$35.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
6/12/2026Reiterated Rating$18.76$31.00Outperform
argenex SE stock logo
ARGX
argenex
6/11/2026Reiterated Rating$882.46$1,000.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
6/10/2026Reiterated Rating$69.99$88.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
6/9/2026Downgrade$122.87$124.00Neutral
argenex SE stock logo
ARGX
argenex
6/4/2026Reiterated Rating$813.14$1,000.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6/2/2026Upgrade$129.69$90.00Neutral
ODTX
Odyssey Therapeutics
6/2/2026Initiated Coverage$16.96$30.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
5/29/2026Reiterated Rating$35.21$55.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
5/28/2026Initiated Coverage$25.21$35.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5/28/2026Reiterated Rating$107.38$125.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
5/27/2026Boost Price Target$84.60$135.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$25.89$42.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/12/2026Reiterated Rating$14.42$12.00Neutral
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
5/8/2026Boost Price Target$6.48$11.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
5/5/2026Reiterated Rating$4.66$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
5/5/2026Reiterated Rating$3.78$11.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/29/2026Boost Price Target$54.04$59.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
4/20/2026Reiterated Rating$4.20$11.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/16/2026Boost Price Target$46.31$58.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
4/16/2026Reiterated Rating$12.24$18.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
4/16/2026Reiterated Rating$4.83$11.00Outperform
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
4/16/2026Reiterated Rating$6.50$13.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
4/13/2026Boost Price Target$64.47$80.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
4/13/2026Reiterated Rating$10.54$22.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4/8/2026Reiterated Rating$102.25$125.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
4/7/2026Reiterated Rating$9.09$22.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
4/2/2026Reiterated Rating$4.50$11.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4/1/2026Boost Price Target$49.16$58.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4/1/2026Lower Price Target$12.67$17.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3/31/2026Reiterated Rating$19.52$30.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3/27/2026Reiterated Rating$4.41$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/18/2026Reiterated Rating$4.95$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
3/17/2026Reiterated Rating$35.68$55.00Outperform
argenex SE stock logo
ARGX
argenex
3/9/2026Reiterated Rating$717.80$1,000.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3/6/2026Boost Price Target$5.10$8.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3/5/2026Boost Price Target$1.08$5.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3/3/2026Boost Price Target$67.77$95.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2/25/2026Boost Price Target$32.29$65.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2/25/2026Boost Price Target$43.50$53.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2/24/2026Initiated Coverage$132.91$110.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
2/24/2026Reiterated Rating$11.71$20.00Outperform
How Elon’s Empire Ends (and how to profit) (Ad)

Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.tc pixel

See Chaikin's full research and the company name here
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$55.99$88.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
2/10/2026Reiterated Rating$5.69$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1/30/2026Reiterated Rating$4.01$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
1/21/2026Reiterated Rating$39.90$55.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
1/15/2026Reiterated Rating$72.74Outperform
Immunome, Inc. stock logo
IMNM
Immunome
1/15/2026Reiterated Rating$20.76$31.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
1/15/2026Reiterated Rating$13.77$18.00Neutral
argenex SE stock logo
ARGX
argenex
1/14/2026Reiterated Rating$810.51$1,000.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
1/13/2026Reiterated Rating$17.43$30.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
1/13/2026Reiterated Rating$9.15$20.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
1/13/2026Boost Price Target$41.12$50.00Outperform
Generation Bio Co. stock logo
GBIO
Generation Bio
12/16/2025Set Price Target$5.39$5.50Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
12/8/2025Reiterated Rating$11.00$20.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
12/2/2025Reiterated Rating$40.07$48.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
11/17/2025Reiterated Rating$108.00$125.00Outperform
argenex SE stock logo
ARGX
argenex
11/14/2025Boost Price Target$894.31$1,000.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
11/10/2025Reiterated Rating$33.21$50.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
11/7/2025Lower Price Target$9.84$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
11/6/2025Reiterated Rating$14.24$26.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
10/30/2025Set Price Target$12.37$9.00
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/28/2025Reiterated Rating$40.45$48.00Outperform
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
10/27/2025Upgrade$1.65$7.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/17/2025Boost Price Target$74.36$110.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10/15/2025Boost Price Target$31.85$70.00Outperform
argenex SE stock logo
ARGX
argenex
10/13/2025Boost Price Target$796.92$880.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/13/2025Boost Price Target$37.89$44.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
10/13/2025Reiterated Rating$3.73$6.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
9/8/2025Initiated Coverage$1.55$4.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/8/2025Reiterated Rating$3.88$6.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
9/8/2025Reiterated Rating$80.89$115.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
9/2/2025Reiterated Rating$8.55$26.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
8/28/2025Reiterated Rating$12.10$22.00Outperform
Generation Bio Co. stock logo
GBIO
Generation Bio
8/13/2025Downgrade$4.05$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
8/7/2025Lower Price Target$7.49$26.00Outperform
ImageneBio, Inc. stock logo
IMA
ImageneBio
7/25/2025Lower Price Target$16.32$23.00Neutral
argenex SE stock logo
ARGX
argenex
6/24/2025Reiterated Rating$550.14$715.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
6/23/2025Reiterated Rating$3.53$11.00Outperform
argenex SE stock logo
ARGX
argenex
6/11/2025Reiterated Rating$575.46$715.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
6/11/2025Reiterated Rating$2.14$5.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
6/5/2025Initiated Coverage$17.48$22.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/19/2025Reiterated Rating$9.09$10.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
5/15/2025Reiterated Rating$2.24$5.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
4/16/2025Lower Price Target$15.66$27.00Neutral
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/16/2025Reiterated Rating$20.59$34.00Outperform
argenex SE stock logo
ARGX
argenex
4/11/2025Reiterated Rating$577.38$715.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
3/20/2025Reiterated Rating$8.64$33.00Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3/14/2025Downgrade$12.50$20.00Neutral
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
3/6/2025Reiterated Rating$0.91$5.00Neutral
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2/6/2025Initiated Coverage$12.72$31.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2/3/2025Reiterated Rating$17.27$40.00Outperform
WATCH THIS BEFORE DECEMBER 8th!! (Ad)

James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.tc pixel

Watch the free breakdown before December 8th to learn more